Orthofix Medical (NASDAQ:OFIX) Research Coverage Started at TD Cowen

TD Cowen started coverage on shares of Orthofix Medical (NASDAQ:OFIX) in a research report report published on Tuesday morning, MarketBeat.com reports. The firm issued a hold rating and a $14.00 price objective on the medical device company’s stock.

A number of other analysts have also recently weighed in on OFIX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Stifel Nicolaus initiated coverage on Orthofix Medical in a research note on Tuesday, October 28th. They set a “buy” rating and a $22.00 price target for the company. Finally, Barrington Research lifted their price objective on shares of Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.00.

Orthofix Medical Stock Down 0.1%

Shares of NASDAQ:OFIX opened at $13.13 on Tuesday. Orthofix Medical has a 1-year low of $10.24 and a 1-year high of $20.48. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.47 and a quick ratio of 1.38. The stock has a market cap of $519.95 million, a P/E ratio of -4.33 and a beta of 0.79. The firm has a fifty day moving average price of $15.12 and a 200 day moving average price of $14.43.

Insider Transactions at Orthofix Medical

In other news, CFO Julie Andrews sold 4,873 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $14.38, for a total value of $70,073.74. Following the completion of the transaction, the chief financial officer owned 58,039 shares in the company, valued at $834,600.82. This trade represents a 7.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Massimo Calafiore sold 9,797 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37. Following the transaction, the chief executive officer owned 217,237 shares in the company, valued at $3,304,174.77. The trade was a 4.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 24,270 shares of company stock valued at $370,958 in the last quarter. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors and hedge funds have recently modified their holdings of OFIX. CWM LLC raised its holdings in Orthofix Medical by 99.0% during the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock worth $28,000 after purchasing an additional 955 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Orthofix Medical in the third quarter valued at $30,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Orthofix Medical during the 2nd quarter worth $147,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in shares of Orthofix Medical by 32.6% in the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 13,297 shares of the medical device company’s stock worth $148,000 after buying an additional 3,271 shares in the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in Orthofix Medical in the 3rd quarter valued at about $148,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.